This report on the global hereditary angioedema market analyzes the
current and future prospects of the market. The report comprises an
elaborate executive summary, including a market snapshot that
provides overall information of various segments and sub-segments.
The research is a combination of primary and secondary research.
Primary research formed the bulk of our research efforts along with
information collected from telephonic interviews and interactions via
e-mails. Secondary research involved study of company websites,
annual reports, press releases, stock analysis presentations, and
various international and national databases. The report provides
market size in terms of US$ Mn for each segment and sub-segment for
the period from 2017 to 2025, considering the macro and micro
environmental factors. Growth rates for each segment within the
global hereditary angioedema market have been determined after a
thorough analysis of past trends, demographics, future trends,
technological developments, and regulatory requirements.
Request for Sample Copy of Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=17135
A detailed qualitative analysis of factors responsible for driving
and restraining market growth and future opportunities has been
provided in the market overview section. This section of the report
also includes market attractiveness analysis that provides a thorough
analysis of the overall competitive scenario in the global hereditary
angioedema market.
Market revenue in terms of US$ Mn for the period between 2015 and
2025 along with the compound annual growth rate (CAGR %) from 2017 to
2025 are provided for all the segments, considering 2016 as the base
year. Market size estimations involved in-depth study of product
features of different types of drug class and various pipeline
products. Additionally, market related factors such as rise in
preference for self-administrable drugs, expiry of market exclusivity
of certain drugs, projected launch of the drugs etc. in various
geographies and historical year-on-year growth have been taken into
consideration while estimating the market size.
Enquiry for discount on this report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=17135
Hereditary Angioedema is a rare genetic disease that is caused by
lack or abnormal functioning of the protein C1 inhibitor protein.
Lack of functional C1 inhibitor protein leads to high volume of
bradykinin, which triggers of blood vessels causing inflammation of
body organs. HAE symptoms are often misdiagnosed for common allergies
or abdominal pain. Many patients are hospitalized due to HAE attacks.
HAE attack in upper airway have proven to be fatal if untreated on
its emergence.
Based on drug class, the global hereditary angioedema market has been
segmented into C1 esterase inhibitor, Selective Bradykinin B2
Receptor Antagonist, Kallikrein Inhibitor others. The C1 esterase
inhibitor is further segmented into drugs namely Cinryze, Berinert
and Ruconest. The segment is anticipated to hold a significant share
of the global market. The others segment is further sun segmented
into conventional and pipeline products. The segment is projected to
dominate the market during the forecast period due to launch of novel
products.
Request a Brochure of the Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=17135
Based on route of administration, the global hereditary angioedema
market is segmented into intravenous, subcutaneous injections and
oral. The subcutaneous injections is anticipated to dominate the
market during the forecast period due to availability of approved
drugs for acute HAE attack are administered subcutaneously,
development of variants of Cinryze and Berinert that can be
administered subcutaneously etc.
Based on the distribution channel, the global hereditary angioedema
market is segmented into hospital pharmacies, retail pharmacies and
others. Ever increasing number of retail pharmacies is attributed
for the significant share of the segment in the global market.
Geographically, the global hereditary angioedema market has been
segmented into six regions: North America, Europe, Asia Pacific and
Rest of the World. In addition, the regions have been further
segmented by major countries from each region.
The report also profiles major players in the hereditary angioedema
market based on various attributes such as company overview,
financial overview, SWOT analysis, key business strategies, product
portfolio, and recent developments. Key companies profiled in the
report include Shire plc, CSL Limited, Pharming Group NV, Ionis
Pharmaceuticals, Inc. and iBio, Inc.
About Us
Transparency Market Research (TMR) is a market intelligence company,
providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers.
TMR’s experienced team of analysts, researchers, and consultants,
use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the
latest and the most reliable information indispensable for businesses
to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such
as pharmaceuticals, chemicals, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These
reports provide in-depth analysis and deep segmentation to possible
micro levels. With wider scope and stratified research methodology,
TMR’s syndicated reports strive to provide clients to serve their
overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment